External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival

Warnnissorn, N; Kanitsap, N; Niparuck, P; Boonsakan, P; Kulalert, P; Limvorapitak, W; Bhoopat, L; Saengboon, S; Chantrathammachart, P; Puavilai, T; Chuncharunee, S

Warnnissorn, N (通讯作者)，Thammasat Univ, Fac Med, Dept Pathol, Pathum Thani, Thailand.

HEMATOLOGY, 2022; 27 (1): 1237

Abstract

Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituxim......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索